Hidradenitis Suppurativa Clinical Trials
Find clinical trials for hidradenitis suppurativa. Search for hidradenitis suppurativa clinical trials in different cities and states across the United States.
RemibrutinibA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Sponsor:
Novartis Pharmaceuticals
Location:
Code:
NCT06799000
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Remibrutinib Dose A
Remibrutinib Dose B
Placebo 1
Placebo 2
SonelokimabStudy to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Sponsor:
MoonLake Immunotherapeutics AG
Location:
Code:
NCT06411379
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonelokimab
Placebo
Observational StudyPhysical Activity in Hidradenitis Suppurativa (HS)
Sponsor:
University of Miami
Location:
Code:
NCT06015438
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Home Exercise Program
Short Exercise Program
EVO101Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
Sponsor:
Virginia Clinical Research, Inc.
Location:
Code:
NCT06645821
Conditions
Hidradenitis Suppurativa (HS)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
EVO101
SonelokimabA Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared with Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa
Sponsor:
MoonLake Immunotherapeutics AG
Location:
Code:
NCT06411899
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonelokimab
Placebo
SBT777101Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
Sponsor:
Sonoma Biotherapeutics, Inc.
Location:
Code:
NCT06361836
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
SBT777101
ElectrothermolysisFeasibility Study on Radiofrequency-Based Selective Electrothermolysis to Investigate Its Effects on Human Skin
Sponsor:
Johns Hopkins University
Location:
Code:
NCT05066113
Conditions
Hidradenitis Suppurativa
Healthy Volunteers
Eligibility Criteria
Sex: All
Age: 22 - 70
Healthy Volunteers: Accepted
Interventions
Radiofrequency-Based treatment
RuxolitinibTopical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
Sponsor:
Milton S. Hershey Medical Center
Location:
Code:
NCT04414514
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Ruxolitinib 1.5% Cream
What are clinical trials for hidradenitis suppurativa (HS)?
Clinical trials for Hidradenitis Suppurativa (HS) are research studies conducted to find new treatments or to evaluate the effectiveness and safety of existing treatments for HS. These trials offer insights that can lead to advancements in treatment methods, improvement in patient care, and even potential cures for this debilitating condition.
HS clinical trials specifically target the complexities of the disease, focusing on reducing the severity of symptoms, preventing flare-ups, and improving the quality of life for those affected. Despite ongoing research, HS remains a challenging condition to treat, highlighting the need for innovative clinical trials.
The importance of HS clinical trials
Clinical trials for Hidradenitis Suppurativa (HS) play a key role in developing new treatments and understanding this condition better. These trials are essential for obtaining regulatory approvals, making sure that any new treatment is safe for patients and effective in treating or managing HS.
HS clinical trials provide valuable information on how the disease progresses, the most effective management practices, and its impact on patients’ lives. This knowledge is crucial for creating comprehensive treatment plans that not just tackle the physical symptoms but also consider the psychological aspects of HS. Ultimately, these studies not only aim to find better treatments but also to increase awareness and understanding of HS, encouraging a more informed and supportive community for those affected.
Types of clinical trials for hidradenitis suppurativa
Clinical trials for Hidradenitis Suppurativa (HS) encompass a wide array of studies, each with a distinct focus aimed at not only enhancing our understanding and treatment of the condition but also exploring various approaches to improve patient care. These include investigating new treatments, developing better diagnostic methods, identifying effective prevention strategies, and efforts to enhance the quality of life for those affected.
Treatment trials
Treatment trials focus on testing new medications or finding new ways to use existing treatments for HS. This includes testing drugs that target specific inflammatory processes, using antibiotics to reduce infection risks, or evaluating surgical options to remove damaged tissue. The goal is to find more effective treatments with fewer side effects, potentially including drugs already on the market but not previously used for HS. These trials aim to improve treatment options for HS patients by identifying what works best.
Diagnostic studies
Diagnostic studies aim to improve how HS is diagnosed, making it quicker and more accurate. This involves using genetic testing, advanced imaging techniques, and other non-invasive methods to identify the disease earlier. The goal is to reduce the time it takes to diagnose HS, allowing for earlier treatment. By finding reliable markers of the disease, these studies help in tailoring the diagnosis to each patient's condition, potentially leading to better management strategies.
Prevention trials
Prevention trials look for ways to prevent HS from developing, especially in people at higher risk. These studies may explore how lifestyle changes, like diet adjustments or quitting smoking, could reduce the risk of developing HS. They also test whether certain medications can prevent HS symptoms in people who are genetically predisposed but have not yet shown symptoms. The aim is to find strategies that can stop the disease before it starts, focusing on early intervention and risk reduction.
Quality of life studies
Quality of life (QoL) studies investigate how to improve the daily lives of people with HS. This includes testing interventions for pain relief, reducing the appearance of scars, and addressing the psychological impacts of HS, such as anxiety and depression. These studies also examine the benefits of patient education, psychological support, and lifestyle counseling in helping patients manage their condition better. The goal is to develop a holistic care approach that not only treats the physical symptoms of HS but also supports the patient's mental and emotional well-being, improving their overall quality of life.
Interested in learning more about hidradenitis suppurativa (HS)? Read all about what HS is, what can cause it, how it's diagnosed, and more in our comprehensive guide!
Who can participate in HS clinical trials?
Individuals interested in participating in Hidradenitis Suppurativa (HS) clinical trials must meet certain criteria to ensure both their safety and the integrity of the trial results. Generally, eligibility is based on having a confirmed diagnosis of HS. Most trials require participants to be of a certain age, typically 18 years or older, although some studies may include younger participants with parental consent.
Eligibility criteria may also consider the severity of the condition, overall health status, treatment history, and specific lifestyle factors. Participants must be able to give informed consent and comply with trial procedures.
What to expect in a clinical trial for hidradenitis suppurativa?
Before joining a clinical trial for hidradenitis suppurativa (HS), participants undergo a screening to confirm their eligibility and are informed in detail about the trial's purpose, procedures, and potential risks and benefits. This ensures they make an informed decision to participate. Once enrolled, they receive baseline assessments before starting treatments, which may vary from new drugs to lifestyle interventions. Throughout the trial, their health and response to treatment are closely monitored, sometimes requiring them to keep a symptom diary.
After the treatment phase, participants undergo final evaluations to measure the effectiveness of the intervention, with some studies also conducting long-term follow-ups. Participation demands a significant time commitment and may involve frequent site visits. It's crucial to understand the costs covered by the trial and the balance between potential benefits and risks.
How to enroll in a clinical trial for hidradenitis suppurativa
Enrolling in a clinical trial for hidradenitis suppurativa through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify Your Trial: Use our intuitive search bar or filter options to locate clinical trials specific to your requirements.
- Select Your Preferred Location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore Study Details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the Health Profile: After clicking on the “Get Started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the Application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.